Otsuka Pharmaceutical and H. Lundbeck A/S announced that FDA approved the labeling update of Abilify Maintena® for extended-release injectable suspension. The approval was based on results from a controlled clinical study of acutely relapsed adults with schizophrenia.
Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding...
Lundbecktoday announced that the FDA has accepted for review a New Drug Application (NDA) for...
Genmab A/S announced today it had reached an in vivo pre-clinical milestone in the collaboration...
H. Lundbeck and Otsuka Pharmaceutical today announced a license and development agreement for Lu AE58054, a selective 5HT 6 receptor antagonist currently in development for the treatment of Alzheimer's disease. Under the terms of the agreement, Lundbeck will grant Otsuka co-development and co-commercialization rights to Lu AE58054.
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today outlined co-promotion plans and summarized the overall progress in their global alliance at a session in Japan with representatives from domestic and international media organizations.
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced the FDA has approved ABILIFY MAINTENA™ (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia. ABILIFY MAINTENA is the first dopamine D2 partial agonist approved as a once- monthly injection.
Recordati has announced the successful conclusion of the acquisition of all rights concerning a portfolio of products indicated for the treatment of rare and other diseases and marketed mainly in the United States of America, from Lundbeck LLC.
COLUMBUS, Ohio (AP) — States not only are having an increasingly difficult time getting the injectable drugs to carry out death sentences, they're also paying as much as 10 times more for the chemicals as in years past.
COPENHAGEN, Denmark (AP) — Lundbeck A/S is changing its distribution system to stop one of its drugs from being used to execute prisoners in the United States.
OKLAHOMA CITY (AP) — Oklahoma prison officials will continue using a sedative as part of the state's three-drug lethal injection protocol despite objections from the drug's manufacturer, a spokesman for the state Department of Corrections said Thursday.
The sole U.S. manufacturer of a sedative that Ohio plans to use to execute death row inmates — and that Oklahoma already uses to do so — said Wednesday it opposes the practice and has asked both states to stop using the drug.
Vernalis plc and H. Lundbeck A/S have entered into a drug discovery collaboration utilising Vernalis' fragment and structure-based drug discovery platform against LRRK2, a kinase target. Inhibitors of this target may have potential utility in the treatment of neurodegenerative indications, such as Parkinson's Disease.
H. Lundbeck A/S (Lundbeck) and Merck, known outside the United States and Canada as MSD, today announced a commercialization agreement for SYCREST(R) (asenapine) sublingual tablets (5 mg, 10 mg).
Lundbeck Inc. has voluntarily recalled two lots of NeoProfen® (ibuprofen lysine) Injection that failed to meet a visible particulate quality requirement. These two lots are the only lots currently available to prescribers and therefore the recall will result in a temporary drug shortage.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., has received approval from the FDA to market Indomethacin for Injection. Indomethacin is therapeutically equivalent to the reference-listed drug INDOCIN I.V., by Lundbeck, Inc.